Scientific Sessions 2025  /  Innovation at the Bench to Prime-Time Therapies at the Bedside  /  Re-writing the Code Using CRISPR-Based Gene Editing in Cardiovascular Disease
Logo

American Heart Association

  37
  0

Final ID:

Re-writing the Code Using CRISPR-Based Gene Editing in Cardiovascular Disease

  • Musunuru, Kiran  ( University of Pennsylvania , Philadelphia , Pennsylvania , United States )
  • Fontana, Marianna  ( University College , London , United Kingdom )
  • Seidman, Christine  ( HARVARD MEDICAL SCHOOL , Boston , Massachusetts , United States )
  • Seidman, Jonathan  ( HARVARD MEDICAL SCHOOL , Boston , Massachusetts , United States )
    • Author Disclosures:
    Kiran Musunuru: DO have relevant financial relationships ; Individual Stocks/Stock Options:Verve Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Beam Therapeutics:Active (exists now) ; Research Funding (PI or named investigator):Nava Therapeutics:Active (exists now) ; Advisor:Capstan Therapeutics:Active (exists now) ; Advisor:LEXEO Therapeutics:Active (exists now) ; Ownership Interest:Variant Bio:Active (exists now) ; Advisor:Verve Therapeutics:Active (exists now) | Marianna Fontana: DO have relevant financial relationships ; Consultant:Alnylam, Alexion/Caelum Biosciences, Astrazeneca, Bridgbio/Eidos, Prothena, Attralus, Intellia Therapeutics, Ionis Pharmaceuticals, Cardior, Lexeo Therapeutics, Janssen Pharmaceuticals, Prothena, Pfizer, Novonordisk, Bayer, Mycardium:Active (exists now) ; Individual Stocks/Stock Options:Mycardium (shares):Active (exists now) ; Individual Stocks/Stock Options:LexeoTherapeutics (share options):Active (exists now) ; Other (please indicate in the box next to the company name):Alnylam, Bridgbio, Astrazeneca, Pfizer.(research grants):Active (exists now) | Christine Seidman: DO have relevant financial relationships ; Other (please indicate in the box next to the company name):Merck, Board of Directors:Active (exists now) ; Advisor:Tenaya:Active (exists now) ; Advisor:Maze:Past (completed) | Jonathan Seidman: DO have relevant financial relationships ; Research Funding (PI or named investigator):Eulamin:Expected (by end of conference) ; Consultant:Cora:Expected (by end of conference)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Innovation at the Bench to Prime-Time Therapies at the Bedside

Monday, 11/10/2025 , 08:00AM - 09:15AM

Cardiovascular Seminar

More abstracts on this topic:
Building vs. Unbuilding Bridges-Therapeutics that Target Actin-Myosin Interactions

Spudich James, Tardiff Jil, Leinwand Leslie, Sucharov Carmen, Buttrick Peter

Gene Therapies for Cardiac and Muscular Diseases

Mcnally Elizabeth, Adler Eric, Hajjar Roger

More abstracts from these authors:

Differential Gene Expression Signatures Underlying Postoperative Atrial Fibrillation

Fan Leon, Tiwari Sameeksha, Seidman Christine, Seidman Jonathan, Wang Hanghang, Muehlschlegel Jochen

Dysregulation of DSCAM and Sclerostin Signaling in Down Syndrome Associated Congenital Heart Disease and Other Phenotypes

Tang Vi, Zhang Qi, Morton Sarah, Mckean David, Narayan Priyanka, Layton Olivia, Sharma Ananya, Seidman Jonathan, Seidman Christine

You have to be authorized to contact abstract author. Please, Login
Not Available